FBR Capital Reiterates Outperform on Cerus (CERS) Following FDA Approval

Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma

-- New Label Claim Expands the Market for Cerus' INTERCEPT Blood System in the United States--

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced U.S. Food and Drug Administration (FDA) approval of the INTERCEPT Blood System for treatment of platelets suspended in 100% plasma. This extended label claim further enhances compatibility with commonly used platelet collection methods.

The INTERCEPT Blood System was initially approved by the FDA in December 2014 for treatment of platelets collected in a... More

Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised draft guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry. The document is intended to provide blood centers with recommendations for controlling the risk of bacterial contamination of platelets, and pathogen reduction technology is included as a recommended method to reduce the risk of transfusion-transmitted sepsis.

The risk of bacterial... More